KURA Stock — Kura Oncology Inc.: Cash, EV, Pipeline

Share price

$11.73

Market cap

$1,043.5M

Cash

$519.0M

Enterprise value

$530.1M

Balance sheet

Cash	$519.0M
Debt	$5.6M
Net cash	$513.4M
Enterprise value	$530.1M
Basic shares	89.0M shares
Fully diluted shares	121.8M shares
Fully diluted market cap	$1,428.6M
Cash per share	$5.83

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading KURA daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23	Ziftomenib	Phase 1	AML; AML With Mutated NPM1; Hematologic Malignancy	—
Feb 12 - Mar 26	Darlifarnib	Phase 1	Solid Tumors With HRAS Alterations; Non Small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC)	—
Jan 12 - Feb 23	ziftomenib	Phase 1	Gastrointestinal Stromal Tumor (GIST); Gastrointestinal Stromal Cancer; Gastrointestinal Stromal Neoplasm	—
Nov 27, 2028 - Jan 8, 2029	Ziftomenib	Phase 2	Advanced Malignant Neoplasm; Acute Myeloid Leukemia; Mixed Lineage Leukemia	—
May 13 - Jun 24	Ziftomenib	Phase 1	Acute Myeloid Leukemia; Mixed Lineage Leukemia Gene Mutation; Refractory AML	—
Dec 13, 2031 - Jan 24, 2032	Ziftomenib	Phase 3	Acute Myeloid Leukemia (AML)	2028

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

ziftomenib

Stage not disclosed · Active Modality: small molecule

Aliases ziftomenib

Target menin

Partnerships Kyowa Kirin (exclusive license to develop, manufacture and commercialize ziftomenib outside of the United States; performance obligations for monotherapy and combination development services)

Indications

Acute Myeloid Leukemia (Phase 3)
Acute Myeloid Leukemia (AML) (Phase 3)
Advanced Malignant Neoplasm (Phase 3)

Status note Menin inhibitor (target/modality per 10-K fallback); the primary 10-Q discloses the Kyowa Kirin ex-US license and ziftomenib-related R&D costs. Stage and indications not stated in the primary excerpts.

Per-asset detail extracted from the 10-Q filed 2026-08-03. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Ziftomenib
Lead indication	Acute Myeloid Leukemia (AML)
Lead phase	Phase 3
Active trials	6
Collaborator trials	5

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07007312	Phase 3	Recruiting	Sponsor	KURA	—	Acute Myeloid Leukemia (AML)	2028
NCT04067336	Phase 2	Active, not recruiting	Sponsor	KURA	—	Advanced Malignant Neoplasm; Acute Myeloid Leukemia; Mixed Lineage Leukemia	—
NCT06001788	Phase 1	Recruiting	Sponsor	KURA	—	AML; AML With Mutated NPM1; Hematologic Malignancy	—
NCT06026410	Phase 1	Recruiting	Sponsor	KURA	—	Solid Tumors With HRAS Alterations; Non Small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC)	—
NCT06655246	Phase 1	Recruiting	Sponsor	KURA	—	Gastrointestinal Stromal Tumor (GIST); Gastrointestinal Stromal Cancer; Gastrointestinal Stromal Neoplasm	—
NCT05735184	Phase 1	Recruiting	Sponsor	KURA	—	Acute Myeloid Leukemia; Mixed Lineage Leukemia Gene Mutation; Refractory AML	—
NCT06930352	Phase 2	Recruiting	Collaborator	Uma Borate	—	Acute Myeloid Leukemia	—
NCT05848687	Phase 2	Recruiting	Collaborator	Tanja Andrea Gruber	AMGN	Lymphoblastic Leukemia	—
NCT07355335	Phase 1	Not yet recruiting	Collaborator	Massachusetts General Hospital	BMY	KMT2A-rearranged; NPM1-mutant Refractory or Relapsed AML	—
NCT06397027	Phase 1	Recruiting	Collaborator	M.D. Anderson Cancer Center	—	Refractory Acute Leukemia; Pediatric Relapsed	—
NCT06448013	Phase 1	Recruiting	Collaborator	M.D. Anderson Cancer Center	—	Acute Myeloid Leukemia	—

Sponsor-matched active trials from ClinicalTrials.gov (6 as sponsor, 5 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 11 active trials for Kura Oncology, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Sphera Biotech	295,039	-483	0.46%	2026-08-14
ADAR1 Capital Management	40,000	no change	0.02%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

KURA — Kura Oncology Inc.